Simplify Disc News Today

The Artificial Disc Replacement Market is anticipated to grow significantly, reaching approximately USD 2,032.6 million by 2033, up from USD 660.3 million in 2023. This growth is projected at a Compound Annual Growth Rate (CAGR) of 11.9% from 2024 to 2033. The market is driven by several key factors, including the i...

Operator: Good day, ladies and gentlemen, and welcome to the NuVasive Fourth Quarter and Full Year 2022 Earnings Conference Call. I would now like to introduce your host for todays call, Ms.

/PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive,...

NuVasive today announced data from an FDA investigational device exemption study supporting its Simplify cervical disc.

Share this article Share this article WASHINGTON, May 12, 2021 /PRNewswire/ -- MCRA, LLC, the leading privately held medical device and biologics advisory firm and Clinical Research Organization (CRO) integrating U.S. and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, Quality Assurance, and Medical Device Cybersecurity, is pleased to announce its role in the successful management and execution of Simplify Medicals two clinical studies and approvals by the U....

Operator Good day. And welcome to the NuVasive Inc. Fourth Quarter and Full Year 2020 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Matt Harbaugh, Executive Vice President and Chief Financial Officer. Thank you. You may begin. Matt Harbaugh -- Executive Vice President and Chief Financial Officer Thank you. Welcome to NuVasives Fourth Quarter and Full Year 2020 Earnings Call. The com...

NuVasive Announces First Quarter 2021 Financial Results -- Net sales increase driven by U.S. procedural volume improvement throughout the quarter and strong international growth -- -- Simplify Cervical Artificial Disc receives FDA approval for two-level cervical total disc replacement -- -- R&D investment increase year over year to advance spine procedural segments and enabling technology roadmap -- News provided by Share this article Share this article SAN DIEGO, May 5, 2021 /PRNewswire/ -- Nu...

Share this article Share this article SAN DIEGO, April 6, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify ® Cervical Artificial Disc (Simplify Disc) received approval from the U.S. Food and Drug Administration (FDA) for two-level cervical total disc replacement (cTDR). "This approval is an incredible achieveme...

FDA Approves NuVasives Simplify Disc For Two-Level Cervical Total Disc Replacement WASHINGTON (dpa-AFX) - NuVasive, Inc. (NUVA), Tuesday announced that the NuVasive Simplify Cervical Artificial Disc received approval from the U.S. Food and Drug Administration for two-level cervical total disc replacement. This approval is an incredible achievement for the Simplify Disc and further broadens the growth opportunities for the NuVasive C360 portfolio, said Massimo Calafiore, executive vice president...

NuVasive Acquires Simplify Medical Simplify Cervical Artificial Disc provides NuVasive most clinically effective technology in the cervical total disc replacement (cTDR) procedure segment Expands growth opportunities and further differentiates Companys comprehensive portfolio across ACDF, PCF, and cTDR procedures News provided by Share this article Share this article SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on tr...